{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:29:41Z","timestamp":1758054581676,"version":"3.44.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,14]]},"DOI":"10.7759\/cureus.92321","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:57:48Z","timestamp":1757912268000},"source":"Crossref","is-referenced-by-count":0,"title":["Etoposide (VP-16)-Containing Oral Palliative Chemotherapies (OPCs) Are Well Tolerated by Elderly Patients With Aggressive Non-Hodgkin Lymphoma: A 10-Year Single-Institute Experience"],"prefix":"10.7759","author":[{"given":"Kenichiro","family":"Takeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yamaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichiro","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop MR","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, et al.. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022, 386:629-39. 10.1056\/NEJMoa2116596","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar M","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, et al.. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022, 399:2294-2308. 10.1016\/S0140-6736(22)00662-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke FL","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al.. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022, 386:640-54. 10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01006-w","article-title":"Novel targeted therapies of T cell lymphomas","volume":"13","author":"I\u017cykowska K","year":"2020","unstructured":"I\u017cykowska K, Rassek K, Korsak D, Przybylski GK. Novel targeted therapies of T cell lymphomas. J Hematol Oncol. 2020, 13:176. 10.1186\/s13045-020-01006-w","journal-title":"J Hematol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz RL","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, et al.. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011, 117:5827-34. 10.1182\/blood-2010-10-312603","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280996","article-title":"Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results","volume":"108","author":"Rai S","year":"2023","unstructured":"Rai S, Kim WS, Ando K, et al.. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023, 108:811-21. 10.3324\/haematol.2022.280996","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008615","article-title":"Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study","volume":"7","author":"Kim WS","year":"2023","unstructured":"Kim WS, Fukuhara N, Yoon DH, et al.. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study. Blood Adv. 2023, 7:4903-12. 10.1182\/bloodadvances.2022008615","journal-title":"Blood Adv"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0019","article-title":"Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma","volume":"24","author":"Reyes C","year":"2019","unstructured":"Reyes C, Engel-Nitz NM, DaCosta Byfield S, et al.. Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin's lymphoma. Oncologist. 2019, 24:1219-28. 10.1634\/theoncologist.2018-0019","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17278","article-title":"DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B-cell lymphoma","volume":"192","author":"Maddox JM","year":"2021","unstructured":"Maddox JM, Horan M, Tafesh L, et al.. DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B-cell lymphoma. Br J Haematol. 2021, 192:e92-4. 10.1111\/bjh.17278","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126997","article-title":"The use of CEP (lomustine, etoposide and prednisone), an all-oral palliative chemotherapy regimen, in aggressive lymphomas","volume":"134","author":"Vasanthamohan L","year":"2019","unstructured":"Vasanthamohan L, Parker B, Mangel J, et al.. The use of CEP (lomustine, etoposide and prednisone), an all-oral palliative chemotherapy regimen, in aggressive lymphomas. Blood. 2019, 134:4131-4131. 10.1182\/blood-2019-126997","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15637","article-title":"A retrospective multicentre study of COCKLE, an oral chemotherapy regimen, as palliative treatment for high grade lymphoma","volume":"185","author":"Maybury B","year":"2019","unstructured":"Maybury B, Kimpton G, Otton S. A retrospective multicentre study of COCKLE, an oral chemotherapy regimen, as palliative treatment for high grade lymphoma. Br J Haematol. 2019, 185:803-6. 10.1111\/bjh.15637","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23422","article-title":"Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy","volume":"112","author":"Coleman M","year":"2008","unstructured":"Coleman M, Martin P, Ruan J, et al.. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008, 112:2228-32. 10.1002\/cncr.23422","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen M","year":"2005","unstructured":"Cullen M, Steven N, Billingham L, et al.. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005, 353:988-98. 10.1056\/NEJMoa050078","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1179\/102453312X13336169155970","article-title":"Metronomic therapy for refractory\/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen","volume":"17 Suppl 1","author":"Coleman M","year":"2012","unstructured":"Coleman M, Ruan G, Elstrom RL, et al.. Metronomic therapy for refractory\/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology. 2012, 17 Suppl 1:S90-2. 10.1179\/102453312X13336169155970","journal-title":"Hematology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.537","article-title":"Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study","volume":"3","author":"Bulley SJ","year":"2022","unstructured":"Bulley SJ, Santarsieri A, Lentell IC, et al.. Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study. EJHaem. 2022, 3:1316-20. 10.1002\/jha2.537","journal-title":"EJHaem"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000039746","article-title":"Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma","volume":"104","author":"Okamoto T","year":"2000","unstructured":"Okamoto T, Nishimura Y, Yamada S, et al.. Long-term administration of oral low-dose topoisomerase II inhibitors, MST-16 and VP-16, for refractory or relapsed non-Hodgkin's lymphoma. Acta Haematol. 2000, 104:128-30. 10.1159\/000039746","journal-title":"Acta Haematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang NH","year":"2007","unstructured":"Dang NH, Pro B, Hagemeister FB, et al.. Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007, 136:439-47. 10.1111\/j.1365-2141.2006.06457.x","journal-title":"Br J Haematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3418-2","article-title":"Multicenter phase 1\/2 study of forodesine in patients with relapsed peripheral T cell lymphoma","volume":"98","author":"Maruyama D","year":"2019","unstructured":"Maruyama D, Tsukasaki K, Uchida T, et al.. Multicenter phase 1\/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. Ann Hematol. 2019, 98:131-42. 10.1007\/s00277-018-3418-2","journal-title":"Ann Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13340","article-title":"Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma","volume":"108","author":"Maruyama D","year":"2017","unstructured":"Maruyama D, Nagai H, Maeda Y, et al.. Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Sci. 2017, 108:2061-8. 10.1111\/cas.13340","journal-title":"Cancer Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001821","article-title":"Brentuximab vedotin in the treatment of CD30+ PTCL","volume":"134","author":"Barta SK","year":"2019","unstructured":"Barta SK, Gong JZ, Porcu P. Brentuximab vedotin in the treatment of CD30+ PTCL. Blood. 2019, 134:2339-45. 10.1182\/blood.2019001821","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/395175-etoposide-vp-16-containing-oral-palliative-chemotherapies-opcs-are-well-tolerated-by-elderly-patients-with-aggressive-non-hodgkin-lymphoma-a-10-year-single-institute-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:57:49Z","timestamp":1757912269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/395175-etoposide-vp-16-containing-oral-palliative-chemotherapies-opcs-are-well-tolerated-by-elderly-patients-with-aggressive-non-hodgkin-lymphoma-a-10-year-single-institute-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.92321","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,14]]}}}